A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/19/2011	DE202011100767U1 Benzoylperoxid 5% Gel als Mittel zur Anwendung gegen Rosazea Benzoyl peroxide 5% gel as a means to use against rosacea
12/15/2011	WO2011156822A2 Pharmaceutical compositions
12/15/2011	WO2011156812A2 Intravaginal administration of misoprostol
12/15/2011	WO2011156811A2 Compounds for treatment of bovine mastitis
12/15/2011	WO2011156803A2 Anti-cellulite composition and method of treating cellulite
12/15/2011	WO2011156786A2 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
12/15/2011	WO2011156780A2 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
12/15/2011	WO2011156775A2 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
12/15/2011	WO2011156759A1 Methods of treating hematological disorders with quinazolinone compounds in selected patients
12/15/2011	WO2011156757A1 Combination of anti-hcv compounds with ribavirin for the treatment of hcv
12/15/2011	WO2011156710A2 Combination therapy with lisdexamphetamine and extended release guanfacine
12/15/2011	WO2011156698A2 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
12/15/2011	WO2011156690A2 Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates
12/15/2011	WO2011156655A2 Novel glp-1 receptor stabilizers and modulators
12/15/2011	WO2011156646A2 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
12/15/2011	WO2011156640A2 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
12/15/2011	WO2011156626A1 Antimicrobial agents
12/15/2011	WO2011156582A2 The use of inducible nitric oxide synthase inhibitors and nitric oxide scavengers to inhibit post-traumatic immunodepression
12/15/2011	WO2011156578A1 Solid compositions
12/15/2011	WO2011156563A2 Oral iron deficiency therapy
12/15/2011	WO2011156554A1 Cyclohexyl-azetidinyl antagonists of ccr2
12/15/2011	WO2011156518A2 Estrogen receptor modulators and uses thereof
12/15/2011	WO2011156481A2 Formulations including amiodarone and salts thereof and methods of their manufacture and use
12/15/2011	WO2011156479A2 Trkb agonists and methods of use
12/15/2011	WO2011156473A1 Crystalline forms of kinase inhibitors
12/15/2011	WO2011156464A1 Crystalline forms of kinase inhibitors
12/15/2011	WO2011156461A1 Crystalline forms of kinase inhibitors
12/15/2011	WO2011156451A2 Compositions and methods for modulating toll-like receptor 2 activation
12/15/2011	WO2011156445A1 Applications of partially and fully sulfated hyaluronan
12/15/2011	WO2011156416A1 Topical antiviral formulations for prevention of transmission of hsv-2
12/15/2011	WO2011156405A2 Oral spray formulations and methods for administration of sildenafil
12/15/2011	WO2011156361A2 Solid dispersions containing kinase inhibitors
12/15/2011	WO2011156355A1 Production method of phenyl guanidine salts and their intermediates
12/15/2011	WO2011156337A2 Macrocyclic hepatitis c serine protease inhibitors
12/15/2011	WO2011156329A2 Methods of treating pain and morphine tolerance via modulation of hedgehog signalling pathway
12/15/2011	WO2011156321A1 Furanyl compounds and the use thereof
12/15/2011	WO2011156248A2 Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
12/15/2011	WO2011156246A1 Novel prolylcarboxypeptidase inhibitors
12/15/2011	WO2011156242A2 Improved anti-lysophospholipid antibody design using antibody structures
12/15/2011	WO2011156220A1 Novel prolylcarboxypeptidase inhibitors
12/15/2011	WO2011156181A1 Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins
12/15/2011	WO2011156119A1 Combination therapy methods for treating proliferative diseases
12/15/2011	WO2011156087A1 Process for the preparation of cis-2-methylspiro (1, 3- oxathiolane 5-3') quinuclidine
12/15/2011	WO2011156003A2 Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
12/15/2011	WO2011155983A1 Opsin-binding ligands, compositions and methods of use
12/15/2011	WO2011155898A1 New antiviral compounds
12/15/2011	WO2011155829A1 Process for extracting materials from biological material
12/15/2011	WO2011155803A2 Novel compound having hearing protection effects
12/15/2011	WO2011155797A2 Hemioxalate salt of crystalline o-desmethylvenlafaxine, preparation method thereof, and pharmaceutical composition thereof
12/15/2011	WO2011155793A2 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
12/15/2011	WO2011155728A2 Composition for preventing or treating osteoporosis, and manufacturing method therefor
12/15/2011	WO2011155689A2 Method for preparing an intermediate of pitavastatin or of the salt thereof
12/15/2011	WO2011155687A1 Novel glycolipid derivative compounds and their therapeutic use for vascular smooth muscle cell hyper-proliferation
12/15/2011	WO2011155640A1 Antimycotic pharmaceutical composition
12/15/2011	WO2011155505A1 Manufacturing method for polyphenol composition
12/15/2011	WO2011155501A1 Pharmaceutical multimeric particles, and manufacturing method for same
12/15/2011	WO2011155451A1 Coated particle and method for producing coated particle
12/15/2011	WO2011154966A1 A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof
12/15/2011	WO2011154958A1 Herbal topical formulation
12/15/2011	WO2011154916A1 5-ala ester formulations and use thereof
12/15/2011	WO2011154871A1 Hepatitis c virus inhibitors
12/15/2011	WO2011154851A1 MODIFIED snRNAs FOR USE IN THERAPY
12/15/2011	WO2011154833A1 Cysteamine derivatives and their use in the treatment of nash
12/15/2011	WO2011154798A1 Novel 1,4-diazepam pde-5 inhibitor derivatives
12/15/2011	WO2011154772A1 Oral veterinary composition for salmonids, comprising 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide and use thereof for the treatment of infectious salmon anaemia (isa) in salmonids
12/15/2011	WO2011154771A1 Use of 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide for the treatment of infectious salmon anaemia (isa) in salmonids
12/15/2011	WO2011154755A1 Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
12/15/2011	WO2011154754A1 USE OF PROSTAGLANDIN F1α AND ITS DERIVATIVES FOR REDUCTION OF INFLAMMATION
12/15/2011	WO2011154739A1 Crystalline forms of thalidomide and processes for their preparation
12/15/2011	WO2011154738A1 Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract
12/15/2011	WO2011154737A1 Morpholino pyrimidines and their use in therapy
12/15/2011	WO2011154725A2 Compositions
12/15/2011	WO2011154724A2 Compositions
12/15/2011	WO2011154708A1 Benzamide derivatives and their use as hsp90 inhibtors
12/15/2011	WO2011154696A1 Anti-inflammatory agents
12/15/2011	WO2011154695A1 Anti-inflammatory agents
12/15/2011	WO2011154678A1 Compounds
12/15/2011	WO2011154677A1 Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
12/15/2011	WO2011154580A1 Novel cxcr4 inhibitors as anti-hiv agents
12/15/2011	WO2011154574A1 Camptothecin derivatives as antitumoural agents
12/15/2011	WO2011154553A2 Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
12/15/2011	WO2011154497A1 Treatment of type 2 diabetes
12/15/2011	WO2011154496A1 Treatment of type 1 diabetes
12/15/2011	WO2011154452A1 New low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses
12/15/2011	WO2011154431A1 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
12/15/2011	WO2011154427A1 MODIFIED snRNAs FOR USE IN THERAPY
12/15/2011	WO2011154418A1 Preparation for vaginal and rectal use and relative production method
12/15/2011	WO2011154414A1 Diversion-resistant microgranules and microtablets
12/15/2011	WO2011154374A1 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
12/15/2011	WO2011154327A1 Nitrogen containing heteroaryl compounds
12/15/2011	WO2011154298A1 NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES
12/15/2011	WO2011154118A1 Quetiapine prolonged-release tablets
12/15/2011	WO2011154013A1 Pharmaceutical composition comprising fenofibric acid
12/15/2011	WO2011154012A1 Mini-tablets comprising porous adsorbent material
12/15/2011	WO2011154009A1 Composition comprising an active principle in an amorphous form and a porous adsorbent material
12/15/2011	WO2011153953A1 Crystalline form of benzylbenzene sglt2 inhibitor
12/15/2011	WO2011153942A1 Cyanoquinoline derivatives
12/15/2011	WO2011153939A1 Agomelatine intermediates and preparation method thereof
12/15/2011	WO2011153929A1 New use of icariin and epimedium flavonoids containing icariin
12/15/2011	WO2011153923A1 Preparation process of dronedarone and its salts

1 ... 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 ... 7860